Fady I Malik - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Fady I Malik

Showing results (11-20 of 120) with videos related to

Pageof 12

Sort By:

Vascular Medicine (London, England)|May 30, 2014

Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery diseaseTimothy A Bauer, Andrew A Wolff, Alan T Hirsch, et al.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 29, 2023

Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trialJeremy M Shefner, Bill Jacobsen, Stuart Kupfer, et al.

International Journal of Toxicology|March 20, 2025

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac MyosinMichael K Pugsley, Darren T Hwee, Brett R Winters, et al.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 8, 2024

Plasma neurofilament analysis in VITALITY-ALSTyrell J Simkins, Stuart Kupfer, Fady I Malik, et al.

Circulation. Heart Failure|May 26, 2010

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failureYou-Tang Shen, Fady I Malik, Xin Zhao, et al.

Muscle & Nerve|November 19, 2017

CK-2127107 amplifies skeletal muscle response to nerve activation in humansJinsy A Andrews, Timothy M Miller, Vipin Vijayakumar, et al.

JACC. Basic to Translational Science|September 5, 2022

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy ParticipantsFady I Malik, Laura A Robertson, Danielle R Armas, et al.

Journal of Neuromuscular Diseases|May 5, 2025

Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALSTyrell Simkins Lead, Jeremy M Shefner, Stuart Kupfer, et al.

Plos One|February 26, 2013

Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to nebulin-deficiencyEun-Jeong Lee, Josine M De Winter, Danielle Buck, et al.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2025

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialStacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, et al.

Pageof 12

Search research articles

Showing results (11-20 of 120) with videos related to

Sort By:

Pageof 12

Vascular Medicine (London, England)|May 30, 2014

Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery diseaseTimothy A Bauer, Andrew A Wolff, Alan T Hirsch, et al.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 29, 2023

Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trialJeremy M Shefner, Bill Jacobsen, Stuart Kupfer, et al.

International Journal of Toxicology|March 20, 2025

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac MyosinMichael K Pugsley, Darren T Hwee, Brett R Winters, et al.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 8, 2024

Plasma neurofilament analysis in VITALITY-ALSTyrell J Simkins, Stuart Kupfer, Fady I Malik, et al.

Circulation. Heart Failure|May 26, 2010

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failureYou-Tang Shen, Fady I Malik, Xin Zhao, et al.

Muscle & Nerve|November 19, 2017

CK-2127107 amplifies skeletal muscle response to nerve activation in humansJinsy A Andrews, Timothy M Miller, Vipin Vijayakumar, et al.

JACC. Basic to Translational Science|September 5, 2022

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy ParticipantsFady I Malik, Laura A Robertson, Danielle R Armas, et al.

Journal of Neuromuscular Diseases|May 5, 2025

Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALSTyrell Simkins Lead, Jeremy M Shefner, Stuart Kupfer, et al.

Plos One|February 26, 2013

Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to nebulin-deficiencyEun-Jeong Lee, Josine M De Winter, Danielle Buck, et al.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2025

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialStacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, et al.

Pageof 12